Novartis-backed eye therapy developer GenSight filed for a $100m offering in the US a year ago, only to withdraw in November.
GenSight Biologics, a France-based gene therapy developer backed by pharmaceutical firm Novartis, is looking to raise €40m ($44m) in an initial public offering in its home country.
GenSight is working on gene therapies to treat neurodegenerative retinal diseases and diseases of the central nervous system. Its lead product candidate, GS010, is in phase 3 trials for a rare mitochondrial disease called Leber’s Hereditary Optic Neuropathy.
The company filed for a $100m IPO in the US in July 2015 before setting…
